Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INB301 in Cancer Cachexia
NCT07584057Phase 2Not yet recruiting
- Sponsor
- Yunnan Baiyao Group Co., Ltd.
- Start
- May 2026
- Primary completion
- Feb 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of INB301 in cancer cachexia, sponsored by Yunnan Baiyao Group Co., Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
INB301
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT07584057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584057.